Biotage AB
STO:BIOT
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| SE |
|
Biotage AB
STO:BIOT
|
11.5B SEK |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
948.1B USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
177.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
138B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
33.5B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
265.3B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.9B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
29.1B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.6B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.6B USD |
Loading...
|
Market Distribution
| Min | -855 316.7% |
| 30th Percentile | 30.8% |
| Median | 44.8% |
| 70th Percentile | 66% |
| Max | 113 764.6% |
Other Profitability Ratios
Biotage AB
Glance View
Biotage AB, a Swedish life sciences company, has carved a significant niche within the analytical and organic chemistry sectors since its inception. The company's core operations revolve around the development of innovative solutions designed to facilitate drug discovery, genetic research, and infection diagnostics. By offering products that simplify and accelerate chemical synthesis, Biotage has become essential to the pharmaceutical and biotechnology industries. The company's product lineup includes automated sample preparation systems, flash chromatography instruments, and peptide synthesis solutions. These tools are indispensable for researchers and lab technicians, making complex laboratory processes more efficient and less time-consuming. Financially, Biotage generates revenue through the sale and distribution of its cutting-edge laboratory instruments and their accompanying consumables. In addition to equipment sales, the company also engages in service contracts and after-sales support, which provides a steady stream of recurring income. This dual model of one-time equipment purchases combined with ongoing service and supply needs ensures a stable revenue base. Biotage stays competitive by continually innovating and refining its technology, ensuring its solutions remain indispensable to scientists addressing critical challenges in medicine, environmental testing, and other fields that demand highly precise chemical processes.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Biotage AB is 62.6%, which is above its 3-year median of 61.9%.
Over the last 3 years, Biotage AB’s Gross Margin has increased from 61.2% to 62.6%. During this period, it reached a low of 60.2% on Mar 31, 2023 and a high of 62.9% on Jun 30, 2024.